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Class B G-protein-coupled receptors are exciting drug targets, yet the structure of a complete re-
ceptor bound to a peptide agonist has remained elusive. Coin et al. present a model of the receptor
CRF1R bound to its native ligand based on partial structures and 44 spatial constraints revealed by
new crosslinking approaches.G-protein-coupled receptors (GPCRs)
represent the largest class of membrane
receptors. They transmit highly diverse
signals across the cell membrane and
form the most important class of drug tar-
gets. Over the last several years, GPCR
structural biology has greatly expanded
our knowledge on the recognition of ago-
nists and antagonists of class A GPCRs,
which form the bulk of this receptor group
(Stevens et al., 2013). In contrast, class B
GPCRs have only 15 members, all of
which are medically important and are
pursued as therapeutic targets. The phys-
iological ligands of class B GPCRs are
peptides rather than small molecules,
and the receptors differ from class A
GPCRs by their large extracellular do-
mains that are the main contributors to
peptide affinity and selectivity. Whereas
the C terminus of peptide agonists is
anchored by the extracellular domain,
the N terminus penetrates the transmem-
brane domain, which is thought to induce
conformational changes at the cyto-
plasmic side, leading to receptor activa-
tion (Pal et al., 2012; Parthier et al., 2009).
Although the crystal structures of
the thermostabilized transmembrane do-
mains of two class B receptors have
recently been solved (Hollenstein et al.,
2013; Siu et al., 2013), structural informa-
tion on ligand recognition is limited to iso-
lated class B extracellular domains bound
to peptide agonists (Pioszak et al., 2008;
Pal et al., 2010). In this issue of Cell,
Coin et al. (2013) report a generalizable
procedure to map the interface betweenthe class B receptor corticotrophin-
releasing factor receptor type 1 (CRF1R)
and one of its ligands, the 40 amino acid
peptide urocortin-1 (Ucn1).
CRF1R and the closely related receptor
CRF2R comprise a subclass of class B
GPCR and play crucial roles inmodulating
stress responses in the central nervous
system, as well as in metabolic regulation.
Their peptide ligands include CRF and
three urocortin peptides (Unc1, Unc2,
and Unc3) (Bale and Vale, 2004). Several
structures related to peptide recognition
by the CRF receptors are known, in-
cluding the CRF1R extracellular domain
bound to the C terminus of CRF (Pioszak
et al., 2008) and the CRF2R extracellular
domain bound to the C-terminal portions
of CRF1 and the three urocortin peptides
(Pal et al., 2010). However, it has been
unclear how the N terminus of the ligand
interacts with the transmembrane domain
to initiate signaling.
To gain insight into ligand binding, the
authors first map Ucn1-binding sites
on CRF1R by expressing 146 receptor
mutants that each contain a genetically
introduced amino acid derivative (azido-
phenylalanine [Azi]), which is a UV-acti-
vated crosslinker. Collectively, mutated
residues nearly covered the complete
extracellular half of the transmembrane
domain, including the extracellular loops
and the linker to the extracellular domain.
UV irradiation of cells activates Azi to
crosslink nearby residues, and 35 of 140
expressed mutant proteins yield covalent
adducts with Ucn1, as detected by immu-Cell 155, Dnoblotting with anti-Unc1 antibodies. This
indicates that these receptor residues are
in close proximity to Ucn1, providing a
map of the Ucn1 binding pocket in the
CRF1R transmembrane domains. Sec-
ond, to position the ligand in the pocket,
the authors generate a new set of
mutants, each one with a genetically
introduced phenylalanine analog, p-20-
fluoroacetyl-phenylalanine (Ffact), at one
of the 23 pocket sites that yield the
strongest Azi crosslinking signals. Ffact
forms covalent bonds with nearby
cysteine residues, which are strategically
placed in the peptide ligand. The cross-
linking results can therefore identify
specific pairs of receptor-peptide ligand
residues in close proximity to each other.
Cells expressing themutant proteins were
incubated with each of five different Ucn1
peptides that contain a cysteine residue
either at position 6, 8, 10, 12, or 14,
yielding 115 possible proximity combina-
tions. Nine of those yielded CRF1R-
Ucn1 crosslinking adducts that could
be identified by immunoblotting, indi-
cating that the eighth, twelfth, and four-
teenth residues of the peptide are in
proximity to the extracellular side of
transmembrane domains 6 and 7. Finally,
the authors derive a conformational
model based on the structures of the
CRF1R extracellular domain/CRF com-
plex, Ucn1, and the CRF1R transmem-
brane domain that fulfills all constraints
of the nine CRF1R-Ucn1 pairs and
the 35 residues of the transmembrane
domain binding pocket.ecember 5, 2013 ª2013 Elsevier Inc. 1207
Figure 1. Elucidating the Interaction of a Class B G-Protein-Coupled Receptor with Its
Ligand
The model is overlaid with the structures of the isolated human CRF1R extracellular domain bound to the
alternative ligand CRF (dark gray), isolated CRF1 (medium gray), and the CRF1R transmembrane domain
(light gray). Residues of the binding pocket in the transmembrane domain identified by Azi photo-
crosslinking are highlighted inmagenta, with proximity residue pairs identified by Ffact crosslinking shown
in stick presentation. Individual transmembrane (TM) helices are denoted. Distances between the Cb
atoms of proximity pairs are indicated by magenta dashed lines.
(A) Side view of the complex.
(B) View from the extracellular side into the TM domain ligand binding pocket.Although the model provides a wealth
of information, it also has some limita-
tions. It positions only an eight amino
acid N-terminal stretch (residues 6–14)
of the 40 amino acid peptide and only
toward transmembrane domain helices 6
and 7 (Figure 1). The latter is surprising,
as the five introduced Ucn1 cysteines
also face helices 1, 2, 3, and 5, whose
residues would be, according to the
model, appropriately spaced for cross-
linking. Second, the model is based on
the X-ray structure of the CRF1R trans-
membrane domain in the inactive con-
formation, bound to a small-molecule
antagonist (Hollenstein et al., 2013),
whereas CRF1R bound to its agonist1208 Cell 155, December 5, 2013 ª2013 ElseUcn1 would be expected to adopt an
active conformation. Yet, the transmem-
brane helices of the inactive structure
and the model are superimposable with
the sole exception of a 3 A˚ inward tilt of
the tip of helix 7, which is required to
satisfy Ffact-Cys and Azi distance con-
straints. Overall, the model provides
important insight into the relative position
of the N terminus of Ucn1 but likely does
not present all aspects of the conforma-
tion of the CRF1R-Ucn1 complex, in-
cluding conformational changes at both
the extracellular and cytoplasmic sides
of the receptor.
The strength of the new approach is
that it can be applied in principle to anyvier Inc.complex for which an initial structural
model exists, that it uses standard lab
technologies in combination with the two
unnatural amino acids (Azi and Ffact
phenylalanine analogs), and that the
spatial constraints are determined in live
cells with intact, fully posttranslationally
modified proteins in their physiological
membrane environment. We therefore
anticipate that it may find widespread
applications. However, it is clear that this
approach is a complement to structure
determination by X-ray crystallography
or nuclear magnetic resonance (NMR)
rather than an alternative to these tech-
niques, and we therefore still await the
first high-resolution structure of a class
B GPCR bound to a physiological peptide
agonist. For now, the model revealed by
the genetically engineered constraints
provides the best alternative.REFERENCES
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